Business Context and Reporting Period
This Form 8-K Current Report from AnaptysBio, Inc. covers the 2019 Annual Meeting of Stockholders held on June 11, 2019. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market under the symbol ANAB.
Key Financial Metrics
This filing is a corporate governance report regarding shareholder votes and does not contain financial performance data. There is no information provided in this document regarding revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing reports the successful adoption of four proposals at the Annual Meeting:
- Director Elections: Hamza Suria, M.B.A., and J. Anthony Ware, M.D., were elected as Class II directors for three-year terms.
- Auditor Ratification: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- Executive Compensation: Shareholders approved the non-binding advisory vote on executive compensation.
- Voting Frequency: Shareholders voted to conduct future advisory votes on executive compensation annually.
Guidance, Outlook, and Risks
This document does not provide management commentary, financial guidance, outlook, or a discussion of risks and contingencies. It strictly details the results of the shareholder vote.
Investor Verification Checklist
- Verify the voting results for the election of directors Hamza Suria and J. Anthony Ware.
- Confirm the ratification of KPMG LLP as the independent auditor.
- Note the shareholder preference for annual executive compensation advisory votes.
- Review the company's most recent 10-K or 10-Q filings for actual financial performance metrics, as they are absent from this 8-K.